STAAR Surgical Co (STAA): Rasio kapitalisasi pasar marang pendapatan

STAAR Surgical Company (STAA) maintains strong pricing power based on the uniqueness of EVO lenses, as evidenced by the price-to-sales ratio, which currently stands at 4.00. Robotic manufacturing integrated with machine vision minimizes defects, although development requires specialized experts. The aggressive expansion of implantable products is currently displacing laser vision correction and capturing the global market.

The high-margin business of STAAR Surgical (STAA) producing implantable lenses with sustainable demand is reflected in the P/S time series. This metric, calculated as the ratio of market capitalization to annual sales volume, determines the cost of each unit of revenue, allowing investors to assess the market premium for the issuer's stable profit generation and technological leadership.